Zacks Research Predicts Higher Earnings for Haemonetics

Haemonetics Co. (NYSE:HAE) – Equities researchers at Zacks Research increased their FY2026 earnings estimates for Haemonetics in a note issued to investors on Monday, December 9th. Zacks Research analyst R. Department now anticipates that the medical instruments supplier will post earnings per share of $5.18 for the year, up from their prior estimate of $5.17. The consensus estimate for Haemonetics’ current full-year earnings is $4.59 per share.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 EPS for the quarter, topping the consensus estimate of $1.09 by $0.03. Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. The firm had revenue of $345.50 million for the quarter, compared to analyst estimates of $342.57 million. During the same period last year, the business earned $0.99 EPS. Haemonetics’s revenue for the quarter was up 8.6% compared to the same quarter last year.

Other analysts also recently issued research reports about the stock. Bank of America began coverage on shares of Haemonetics in a research report on Wednesday, September 11th. They issued a “neutral” rating and a $85.00 price target for the company. Citigroup reduced their target price on shares of Haemonetics from $94.00 to $85.00 and set a “neutral” rating for the company in a report on Thursday, August 22nd. Barrington Research reissued an “outperform” rating and set a $108.00 price target on shares of Haemonetics in a report on Wednesday, December 4th. BTIG Research assumed coverage on shares of Haemonetics in a research note on Tuesday, September 10th. They issued a “buy” rating and a $112.00 price objective on the stock. Finally, JPMorgan Chase & Co. assumed coverage on shares of Haemonetics in a report on Friday, December 6th. They issued an “overweight” rating and a $116.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $108.78.

Haemonetics Stock Down 0.6 %

Haemonetics stock opened at $83.34 on Wednesday. The company has a market capitalization of $4.19 billion, a P/E ratio of 34.58, a PEG ratio of 1.26 and a beta of 0.38. The company has a debt-to-equity ratio of 1.39, a quick ratio of 2.09 and a current ratio of 3.49. Haemonetics has a fifty-two week low of $70.25 and a fifty-two week high of $97.97. The stock has a 50-day simple moving average of $80.83 and a 200-day simple moving average of $81.62.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Quarry LP purchased a new stake in shares of Haemonetics during the 2nd quarter valued at $39,000. Daiwa Securities Group Inc. purchased a new stake in shares of Haemonetics during the 2nd quarter worth about $82,000. Canada Pension Plan Investment Board purchased a new stake in shares of Haemonetics during the 2nd quarter worth about $83,000. Nisa Investment Advisors LLC raised its position in Haemonetics by 124.2% in the third quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier’s stock valued at $92,000 after purchasing an additional 632 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Haemonetics in the second quarter valued at approximately $140,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.